These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

240 related items for PubMed ID: 18641578

  • 1. [Pilot study of a new matrix therapy agent (RGTA OTR4120) in treatment-resistant corneal ulcers and corneal dystrophy].
    Chebbi CK, Kichenin K, Amar N, Nourry H, Warnet JM, Barritault D, Baudouin C.
    J Fr Ophtalmol; 2008 May; 31(5):465-71. PubMed ID: 18641578
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Healing of resistant corneal neurotrophic ulcers using a matrix regenerating agent.
    Cochener B, Zagnoli C, Hugny-Larroque C, Derrien S.
    J Fr Ophtalmol; 2019 Feb; 42(2):159-165. PubMed ID: 30573293
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The healing of alkali-injured cornea is stimulated by a novel matrix regenerating agent (RGTA, CACICOL20): a biopolymer mimicking heparan sulfates reducing proteolytic, oxidative and nitrosative damage.
    Cejkova J, Olmiere C, Cejka C, Trosan P, Holan V.
    Histol Histopathol; 2014 Apr; 29(4):457-78. PubMed ID: 24105332
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A New Matrix Therapy Agent for Faster Corneal Healing and Less Ocular Discomfort Following Epi-off Accelerated Corneal Cross-linking in Progressive Keratoconus.
    Gumus K, Guerra MG, de Melo Marques SH, Karaküçük S, Barritault D.
    J Refract Surg; 2017 Mar 01; 33(3):163-170. PubMed ID: 28264130
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Matrix therapy with RGTA OTR4120 improves healing time and quality in hairless rats with deep second-degree burns.
    Zakine G, Barbier V, Garcia-Filipe S, Luboinski J, Papy-Garcia D, Chachques JC, Carpentier A, Barritault D.
    Plast Reconstr Surg; 2011 Feb 01; 127(2):541-550. PubMed ID: 21285759
    [Abstract] [Full Text] [Related]

  • 14. Case Reports for Topical Treatment of Corneal Ulcers with a New Matrix Therapy Agent or RGTA® in Dogs.
    Martinez JA, Chiappini F, Barritault D.
    Vet Sci; 2019 Dec 13; 6(4):. PubMed ID: 31847217
    [Abstract] [Full Text] [Related]

  • 15. Use of Plasma Rich in Growth Factors and ReGeneraTing Agent Matrix for the Treatment of Corneal Diseases.
    Sánchez-Ávila RM, Uribe-Badillo E, Fernández-Vega González C, Muruzabal F, de la Sen-Corcuera B, Baamonde B, Quirós LM, Anitua E, Merayo-Lloves J.
    Vision (Basel); 2021 Jul 02; 5(3):. PubMed ID: 34287367
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Topical Treatment of Persistent Epithelial Defects with a Matrix Regenerating Agent.
    Sevik MO, Turhan SA, Toker E.
    J Ocul Pharmacol Ther; 2018 Nov 02; 34(9):621-627. PubMed ID: 30312119
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of a new matrix regenerating agent in patients with Sjögren syndrome and superficial ulcerative keratitis resistant to conventional therapy: A report of 3 cases.
    Fajnkuchen F, Barritault D, Giocanti-Aurégan A.
    Medicine (Baltimore); 2018 Mar 02; 97(10):e9935. PubMed ID: 29517701
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.